A citation-based method for searching scientific literature

Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman, Abhinav Deol, Patrick M Reagan, Patrick Stiff, Ian W Flinn, Umar Farooq, Andre Goy, Peter A McSweeney, Javier Munoz, Tanya Siddiqi, Julio C Chavez, Alex F Herrera, Nancy L Bartlett, Jeffrey S Wiezorek, Lynn Navale, Allen Xue, Yizhou Jiang, Adrian Bot, John M Rossi, Jenny J Kim, William Y Go, Sattva S Neelapu. Lancet Oncol 2019
Times Cited: 846







List of co-cited articles
723 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
Gustaaf W van Imhoff, Andrew McMillan, Matthew J Matasar, John Radford, Kirit M Ardeshna, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies,[...]. J Clin Oncol 2017
100
4

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Matthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, Thomas E Witzig, Corinne Haioun, Carrie A Thompson, Richard Delarue, Ivana N Micallef, Frédéric Peyrade, William R Macon,[...]. J Clin Oncol 2014
219
4

TRUCKs: the fourth generation of CARs.
Markus Chmielewski, Hinrich Abken. Expert Opin Biol Ther 2015
289
4


Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, Pamela McKay, Tycel Phillips, Sarit Assouline, Connie Lee Batlevi, Phillip Campbell, Vincent Ribrag, Gandhi Laurent Damaj,[...]. Lancet Oncol 2020
113
4

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Ian W Flinn, Carole B Miller, Kirit M Ardeshna, Scott Tetreault, Sarit E Assouline, Jiri Mayer, Michele Merli, Scott D Lunin, Andrew R Pettitt, Zoltan Nagy,[...]. J Clin Oncol 2019
128
4

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Ajay K Gopal, Brad S Kahl, Sven de Vos, Nina D Wagner-Johnston, Stephen J Schuster, Wojciech J Jurczak, Ian W Flinn, Christopher R Flowers, Peter Martin, Andreas Viardot,[...]. N Engl J Med 2014
745
4

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Maria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, Peter Kufer, Max S Topp, Hermann Einsele, Richard Noppeney, Georg Hess, Stefan Kallert, Andreas Mackensen,[...]. J Clin Oncol 2016
258
4

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
Gloria Iacoboni, Guillermo Villacampa, Nuria Martinez-Cibrian, Rebeca Bailén, Lucia Lopez Corral, Jose M Sanchez, Manuel Guerreiro, Ana Carolina Caballero, Alberto Mussetti, Juan-Manuel Sancho,[...]. Cancer Med 2021
23
17

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
M-L Schubert, M Schmitt, L Wang, C A Ramos, K Jordan, C Müller-Tidow, P Dreger. Ann Oncol 2021
55
7

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
P Feugier, A Van Hoof, C Sebban, P Solal-Celigny, R Bouabdallah, C Fermé, B Christian, E Lepage, H Tilly, F Morschhauser,[...]. J Clin Oncol 2005
4

Inducible apoptosis as a safety switch for adoptive cell therapy.
Antonio Di Stasi, Siok-Keen Tey, Gianpietro Dotti, Yuriko Fujita, Alana Kennedy-Nasser, Caridad Martinez, Karin Straathof, Enli Liu, April G Durett, Bambi Grilley,[...]. N Engl J Med 2011
962
4

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
Gerald P Linette, Edward A Stadtmauer, Marcela V Maus, Aaron P Rapoport, Bruce L Levine, Lyndsey Emery, Leslie Litzky, Adam Bagg, Beatriz M Carreno, Patrick J Cimino,[...]. Blood 2013
697
4

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Caron A Jacobson, Julio C Chavez, Alison R Sehgal, Basem M William, Javier Munoz, Gilles Salles, Pashna N Munshi, Carla Casulo, David G Maloney, Sven de Vos,[...]. Lancet Oncol 2022
15
26

Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.
Paolo Strati, Sairah Ahmed, Partow Kebriaei, Loretta J Nastoupil, Catherine M Claussen, Grace Watson, Sandra B Horowitz, Anne Rain T Brown, Bryan Do, Maria A Rodriguez,[...]. Blood Adv 2020
59
5

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.
C Imai, K Mihara, M Andreansky, I C Nicholson, C-H Pui, T L Geiger, D Campana. Leukemia 2004
497
3

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.
Kris M Mahadeo, Sajad J Khazal, Hisham Abdel-Azim, Julie C Fitzgerald, Agne Taraseviciute, Catherine M Bollard, Priti Tewari, Christine Duncan, Chani Traube, David McCall,[...]. Nat Rev Clin Oncol 2019
116
3

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.
Kevin R Parker, Denis Migliorini, Eric Perkey, Kathryn E Yost, Aparna Bhaduri, Puneet Bagga, Mohammad Haris, Neil E Wilson, Fang Liu, Khatuna Gabunia,[...]. Cell 2020
121
3

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.
Judith Feucht, Jie Sun, Justin Eyquem, Yu-Jui Ho, Zeguo Zhao, Josef Leibold, Anton Dobrin, Annalisa Cabriolu, Mohamad Hamieh, Michel Sadelain. Nat Med 2019
188
3

CAR-T efficacy: is conditioning the key?
Sattva S Neelapu. Blood 2019
43
6

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Carlos A Ramos, Rayne Rouce, Catherine S Robertson, Amy Reyna, Neeharika Narala, Gayatri Vyas, Birju Mehta, Huimin Zhang, Olga Dakhova, George Carrum,[...]. Mol Ther 2018
106
3

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.
Kole T Roybal, Levi J Rupp, Leonardo Morsut, Whitney J Walker, Krista A McNally, Jason S Park, Wendell A Lim. Cell 2016
488
3

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
Barbara Savoldo, Carlos Almeida Ramos, Enli Liu, Martha P Mims, Michael J Keating, George Carrum, Rammurti T Kamble, Catherine M Bollard, Adrian P Gee, Zhuyong Mei,[...]. J Clin Invest 2011
702
3

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.
Mythili Koneru, Terence J Purdon, David Spriggs, Susmith Koneru, Renier J Brentjens. Oncoimmunology 2015
241
3

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.
Na Wang, Xuelian Hu, Wenyue Cao, Chunrui Li, Yi Xiao, Yang Cao, Chaojiang Gu, Shangkun Zhang, Liting Chen, Jiali Cheng,[...]. Blood 2020
97
3

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
Gunilla Enblad, Hannah Karlsson, Gustav Gammelgård, Jessica Wenthe, Tanja Lövgren, Rose Marie Amini, Kristina I Wikstrom, Magnus Essand, Barbara Savoldo, Helene Hallböök,[...]. Clin Cancer Res 2018
108
3

Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity.
Spencer Park, Enda Shevlin, Yogindra Vedvyas, Marjan Zaman, Susan Park, Yen-Michael S Hsu, Irene M Min, Moonsoo M Jin. Sci Rep 2017
78
3

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Michael M Boyiadzis, Madhav V Dhodapkar, Renier J Brentjens, James N Kochenderfer, Sattva S Neelapu, Marcela V Maus, David L Porter, David G Maloney, Stephan A Grupp, Crystal L Mackall,[...]. J Immunother Cancer 2018
113
3


Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
Michael C Jensen, Leslie Popplewell, Laurence J Cooper, David DiGiusto, Michael Kalos, Julie R Ostberg, Stephen J Forman. Biol Blood Marrow Transplant 2010
374
3

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Sonia Guedan, Avery D Posey, Carolyn Shaw, Anna Wing, Tong Da, Prachi R Patel, Shannon E McGettigan, Victoria Casado-Medrano, Omkar U Kawalekar, Mireia Uribe-Herranz,[...]. JCI Insight 2018
259
3

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Waleed Haso, Daniel W Lee, Nirali N Shah, Maryalice Stetler-Stevenson, Constance M Yuan, Ira H Pastan, Dimiter S Dimitrov, Richard A Morgan, David J FitzGerald, David M Barrett,[...]. Blood 2013
367
3

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies.
Marco Ruella, Marcela V Maus. Comput Struct Biotechnol J 2016
156
3

Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia.
Xin He, Zijie Feng, Jian Ma, Sunbin Ling, Yan Cao, Buddha Gurung, Yuan Wu, Bryson W Katona, Kienan P O'Dwyer, Don L Siegel,[...]. Blood 2020
66
4

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.
Haiying Qin, Sneha Ramakrishna, Sang Nguyen, Thomas J Fountaine, Anusha Ponduri, Maryalice Stetler-Stevenson, Constance M Yuan, Waleed Haso, Jack F Shern, Nirali N Shah,[...]. Mol Ther Oncolytics 2018
123
3

The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Sahra Ali, Rune Kjeken, Christiane Niederlaender, Greg Markey, Therese S Saunders, Mona Opsata, Kristine Moltu, Bjørn Bremnes, Eirik Grønevik, Martine Muusse,[...]. Oncologist 2020
26
11

Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
Sarwish Rafiq, Christopher S Hackett, Renier J Brentjens. Nat Rev Clin Oncol 2020
335
3

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.
Diogo Gomes-Silva, Malini Mukherjee, Madhuwanti Srinivasan, Giedre Krenciute, Olga Dakhova, Yueting Zheng, Joaquim M S Cabral, Cliona M Rooney, Jordan S Orange, Malcolm K Brenner,[...]. Cell Rep 2017
127
3

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.
Christopher C Kloss, Maud Condomines, Marc Cartellieri, Michael Bachmann, Michel Sadelain. Nat Biotechnol 2013
543
3

Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.
Shivani Srivastava, Alexander I Salter, Denny Liggitt, Sushma Yechan-Gunja, Megha Sarvothama, Kirsten Cooper, Kimberly S Smythe, Jarrod A Dudakov, Robert H Pierce, Christoph Rader,[...]. Cancer Cell 2019
125
3

Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations.
Robert Weinkove, Philip George, Nathaniel Dasyam, Alexander D McLellan. Clin Transl Immunology 2019
122
3

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.
Kevin J Curran, Steven P Margossian, Nancy A Kernan, Lewis B Silverman, David A Williams, Neerav Shukla, Rachel Kobos, Christopher J Forlenza, Peter Steinherz, Susan Prockop,[...]. Blood 2019
95
3

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Anas Younes, Armando Santoro, Margaret Shipp, Pier Luigi Zinzani, John M Timmerman, Stephen Ansell, Philippe Armand, Michelle Fanale, Voravit Ratanatharathorn, John Kuruvilla,[...]. Lancet Oncol 2016
624
3


Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.
Richard J Lin, Stephanie M Lobaugh, Martina Pennisi, Hei Ton Chan, Yakup Batlevi, Josel D Ruiz, Theresa A Elko, Molly A Maloy, Connie L Batlevi, Parastoo B Dahi,[...]. Haematologica 2021
18
16

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Ibrahim Yakoub-Agha, Christian Chabannon, Peter Bader, Grzegorz W Basak, Halvard Bonig, Fabio Ciceri, Selim Corbacioglu, Rafael F Duarte, Hermann Einsele, Michael Hudecek,[...]. Haematologica 2020
122
3


Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
David Porter, Noelle Frey, Patricia A Wood, Yanqiu Weng, Stephan A Grupp. J Hematol Oncol 2018
219
3

Tumor Antigen Escape from CAR T-cell Therapy.
Robbie G Majzner, Crystal L Mackall. Cancer Discov 2018
336
3

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.
Chuan Tong, Yajing Zhang, Yang Liu, Xingyu Ji, Wenying Zhang, Yelei Guo, Xiao Han, Dongdong Ti, Hanren Dai, Chunmeng Wang,[...]. Blood 2020
66
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.